Logo image of DNAC

Social Capital Suvretta Holdings Corporation III (DNAC) Stock Fundamental Analysis

NASDAQ:DNAC - Nasdaq - KYG8253W1096 - Common Stock

9.28  -0.72 (-7.2%)

After market: 9.6 +0.32 (+3.45%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to DNAC. DNAC was compared to 0 industry peers in the Unkown industry. The financial health of DNAC is average, but there are quite some concerns on its profitability. DNAC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DNAC has reported negative net income.
DNAC Yearly Net Income VS EBIT VS OCF VS FCFDNAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 -500K -1M -1.5M -2M

1.2 Ratios

Industry RankSector Rank
ROA -2.51%
ROE N/A
ROIC -2.04%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DNAC Yearly ROA, ROE, ROICDNAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 -0.2 -0.4 -0.6 -0.8

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DNAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNAC Yearly Profit, Operating, Gross MarginsDNAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021

More info and screens

5

2. Health

2.1 Basic Checks

DNAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DNAC Yearly Shares OutstandingDNAC Yearly Shares OutstandingYearly Shares Outstanding 2021 10M 20M 30M
DNAC Yearly Total Debt VS Total AssetsDNAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 50M 100M 150M 200M 250M

2.2 Solvency

DNAC has an Altman-Z score of 13.37. This indicates that DNAC is financially healthy and has little risk of bankruptcy at the moment.
DNAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.37
ROIC/WACCN/A
WACCN/A
DNAC Yearly LT Debt VS Equity VS FCFDNAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 50M 100M 150M 200M

2.3 Liquidity

DNAC has a Current Ratio of 0.11. This is a bad value and indicates that DNAC is not financially healthy enough and could expect problems in meeting its short term obligations.
DNAC has a Quick Ratio of 0.11. This is a bad value and indicates that DNAC is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
DNAC Yearly Current Assets VS Current LiabilitesDNAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 500K 1M 1.5M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31849.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DNAC Yearly Revenue VS EstimatesDNAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021
DNAC Yearly EPS VS EstimatesDNAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNAC Price Earnings VS Forward Price EarningsDNAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNAC Per share dataDNAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DNAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Social Capital Suvretta Holdings Corporation III

NASDAQ:DNAC (7/11/2022, 8:00:01 PM)

After market: 9.6 +0.32 (+3.45%)

9.28

-0.72 (-7.2%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.13%
Inst Owner Change0%
Ins Owners2.01%
Ins Owner Change0%
Market Cap295.94M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.45
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.51%
ROE N/A
ROCE N/A
ROIC -2.04%
ROICexc N/A
ROICexgc -2.04%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z 13.37
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31849.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A